Drug Development for Rare Diseases (häftad)
Fler böcker inom
Format
Inbunden (Hardback)
Språk
Engelska
Serie
Chapman & Hall CRC Biostatistics Series
Antal sidor
222
Utgivningsdatum
2023-02-13
Förlag
Taylor & Francis Ltd
Dimensioner
234 x 156 x 14 mm
Vikt
504 g
ISBN
9780367518349

Drug Development for Rare Diseases

av Bo Yang, Yang Song, Yijie Zhou
Inbunden,  Engelska, 2023-02-13
1891
Köp
Spara som favorit
  • Skickas från oss inom 7-10 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Finns även som
Visa alla 2 format & utgåvor
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges. Key Features: * Rare disease. * Drug development. * Innovative clinical trial design. * Regulatory approval. * Real-world evidence.
Visa hela texten

Passar bra ihop

  1. Drug Development for Rare Diseases
  2. +
  3. Everything Is Tuberculosis

De som köpt den här boken har ofta också köpt Everything Is Tuberculosis av John Green (inbunden).

Köp båda 2 för 2124 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Fler böcker av författarna

Bo Yang, Yang Song, Yijie Zhou

Övrig information

Bo Yang is the Vice President, Biometrics and Real World Evidence at Vertex Pharmaceuticals, USA. Yang Song is the Executive Director, Biostatistics Group Head of Pipeline Development at Vertex Pharmaceuticals, USA. Yijie Zhou is the Executive Director, Real World Statistics and Analytics at Vertex Pharmaceuticals, USA.

Du kanske gillar